Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy

Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy

US Patent 10314905 · Granted Jun 11, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use f2024
Composition of radioactive and non-radioactive microparticles2024
Lassa vaccine2024
Recombinant measles virus expressing zika virus prM and E proteins2024
Recombinant measles vaccine expressing hTERT2022
Live recombinant measles-M2 virus—its use in eliciting immunity against influenz2021
Dengue virus chimeric polyepitope composed of fragments of non-structural protei2021
Compositions and methods comprising measles virus defective interfering particle2021
Compositions and methods comprising measles virus defective interfering particle2021
Use of a genetically modified infectious measles virus with enhanced pro-apoptot2021
Use of a genetically modified infectious measles virus with enhanced pro-apoptot2021
Use of a genetically modified infectious measles virus with enhanced pro-apoptot2021